Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ALX Oncology
Biotech
CatalYm catalyzes C-suite shake-up—Chutes & Ladders
CatalYm catalyzes C-suite shake-up. Character draws new leadership. Amgen adds top cancer scientist to research team.
Darren Incorvaia
,
Zoey Becker
Sep 19, 2025 8:30am
Pfizer vet lands first CEO role—Chutes & Ladders
Aug 15, 2025 8:30am
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Apr 25, 2025 2:25pm
ALX lays off 30% of staff to pay for more trials of CD47 blocker
Mar 5, 2025 9:40am
Flagship-backed biotechs name new leaders—Chutes & Ladders
Nov 15, 2024 8:30am
ALX's fizzling CD47 response rate sends stock spiraling down
Aug 1, 2024 5:34am
